Robert E Tigelaar

6355238, Mar 12, 2002

Mar 21, 1997

08/822940

Richard L. Edelson - Westport CT
Francis P. Gasparro - Hamden CT
Robert E. Tigelaar - Guilford CT

Yale University - New Haven CT

A01N 6300

424 931, 435325, 530300

Methods and pharmaceutical compositions for modifying the immune response of a mammal to a specific antigen are provided. The methods include treating an antigen presenting cell to enhance expression of a major histocompatibility complex molecule and reacting the treated antigen presenting cell with the antigen extracorporeally to form an antigen-associated antigen presenting cell.

20060264360, Nov 23, 2006

Apr 11, 2003

10/510569

Michael Girardi - Madison CT, US
Robert Tigelaar - New Haven CT, US
Michael Sherling - Brookline MA, US
John Shires - Stone Mountain GA, US
Adrian Hayday - Kent, GB
Efatathios Theodoridis - London, GB

Yale University Office Of Cooperstive Research - New Haven CT
King's College London - London

A61K 38/22

514012000

The invention relates to a method of treating inflammatory conditions in a subject comprising administering to a subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4polypeptide variant. The invention also provides a method of promoting wound healing in a subject comprising administering to the subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4polypeptide variant. The invention also relates to methods of treating the above mentioned conditions in a subject comprising administering to the subject a nucleic acid encoding a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to pharmaceutical compositions comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4polypeptide variant, or salt thereof, and a pharmaceutically acceptable carrier.

20090317457, Dec 24, 2009

May 22, 2009

12/471334

Michael Girardi - Madison CT, US
Robert E. Tigelaar - Madison CT, US
Michael A. Sherling - Brookline MA, US
John Shires - Stone Mountain GA, US
Adrian C. Hayday - Kent, GB
Efstathios Theodoridis - London, GB

Yale University - New Haven CT
King's College London - London

A61K 9/127
A61K 38/16
A61K 9/10
A61K 31/7088

424450, 514 12, 424484, 514 44 R

The invention relates to a method of treating inflammatory conditions in a subject comprising administering to a subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also provides a method of promoting wound healing in a subject comprising administering to the subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to methods of treating the above mentioned conditions in a subject comprising administering to the subject a nucleic acid encoding a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to pharmaceutical compositions comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant, or salt thereof, and a pharmaceutically acceptable carrier.

56519931, Jul 29, 1997

Nov 18, 1992

7/977672

Richard L. Edelson - Westport CT
Francis P. Gasparro - Hamden CT
Robert E. Tigelaar - Guilford CT

Yale University - New Haven CT

A61K 3514

424534

Methods and pharmaceutical compositions for modifying the immune response of a mammal to a specific antigen are provided. The methods include treating an antigen presenting cell to enhance expression of a major histocompatibility complex molecule and reacting the treated antigen presenting cell with the antigen extracorporeally to form an antigen-associated antigen presenting cell.

20220280562, Sep 8, 2022

Nov 18, 2021

17/529566

- Dusseldorf, DE
- New Haven CT, US
Robert TIGELAAR - New Haven CT, US
Richard EDELSON - Westport CT, US
Michael GIRARDI - Madison CT, US
Karsten HENCO - Dusseldorf, DE
Adrian HAYDAY - Kent, GB

A61K 35/15
C12N 5/0784
A61K 39/395
C12N 5/0786

The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.

20220259556, Aug 18, 2022

Oct 21, 2021

17/507002

- Dusseldorf, DE
- New Haven CT, US
Justin DUCKWORTH - Surrey, GB
Adrian HAYDAY - Kent, GB
Richard EDELSON - Westport CT, US
Robert TIGELAAR - New Haven CT, US
Michael GIRARDI - Madison CT, US

C12N 5/0784
A61K 35/15

The present invention relates to methods for producing immuno-suppressive dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from autoimmune diseases, hypersensitivity diseases, rejection on solid-organ transplantation and/or Graft-versus-Host disease.

20170128490, May 11, 2017

Jul 3, 2015

15/323219

- Dusseldorf, DE
- New Haven CT, US
ROBERT TIGELAAR - New Haven CT, US
RICHARD EDELSON - Westport CT, US
MICHAEL GIRARDI - Madison CT, US
KARSTEN HENCO - Dusseldorf, DE
ADRIAN HAYDAY - Kent, GB

A61K 35/15
A61K 39/395
C12N 5/0786

The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.

20160298082, Oct 13, 2016

Jan 2, 2014

14/759012

- Düsseldorf, DE
- New Haven CT, US
Justin DUCKWORTH - Surrey, GB
Adrian HAYDAY - Kent, GB
Richard EDELSON - Westport CT, US
Robert TIGELAAR - New Haven CT, US
Michael GIRARDI - Madison CT, US

C12N 5/0784
A61K 35/15

The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.